⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for A Randomized Phase 2/3 Multi-Center Study of SM-88 in Patients With Metastatic Pancreatic Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Randomized Phase 2/3 Multi-Center Study of SM-88 in Patients With Metastatic Pancreatic Cancer

Official Title: A Randomized Phase 2/3 Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer Whose Disease Has Progressed or Recurred

Study ID: NCT03512756

Study Description

Brief Summary: A prospective, open-label phase 2/3 trial in metastatic pancreatic cancer subjects who have failed two lines of prior systemic therapy. The trial is designed to evaluate the safety and efficacy of SM-88 used with MPS (methoxsalen, phenytoin and sirolimus) in pancreatic cancer and will measure multiple endpoints, including overall survival, progression free survival, relevant biomarkers, quality of life, safety, and overall response rate. (Part 1 enrollment complete) In the initial stage of the trial (36 subjects), two dose levels of SM-88's metyrosine-derivative was evaluated. (Part 2 actively enrolling) The second part will consist of a subsequent expansion of the trial to further assess safety and efficacy of SM-88 used with MPS containing the selected SM-88 RP2D from Part 1. A total of 250 subjects in the second part will be randomized 1:1 either to the SM-88 arm (125 subjects) or Physician's Choice of therapy for the Control Arm (125 subjects). Subjects should have previously received two lines of prior systemic therapy.

Detailed Description: Please refer to Inclusion/Exclusion Criteria and Summary

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

University of Alabama at Birmingham, Birmingham, Alabama, United States

City Of Hope, Duarte, California, United States

Sarcoma Oncology Research Center, Santa Monica, California, United States

Hartford Healthcare Cancer, New Britain, Connecticut, United States

H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

Advent Health Florida Hospital Tampa, Tampa, Florida, United States

June E. Nylen Cancer Center, Sioux City, Iowa, United States

University Medical Center, New Orleans, Louisiana, United States

Karmanos Cancer Institute, Detroit, Michigan, United States

Washington University, Saint Louis, Missouri, United States

New York Cancer and Blood Specialist, Bronx, New York, United States

North Shore Hematology Oncology, East Setauket, New York, United States

NY Cancer and Blood Specialist, East Setauket, New York, United States

NYU Langone Health, New York, New York, United States

Central Park Hematology & Oncology, New York, New York, United States

Weill Cornell, New York, New York, United States

The Ohio State University, Columbus, Ohio, United States

Texas Oncology-Baylor, Dallas, Texas, United States

MD Anderson, Houston, Texas, United States

Virginia Mason Medical Center, Seattle, Washington, United States

Contact Details

Name: Giuseppe DelPriore, MD, MPH

Affiliation: Tyme, Inc

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: